Last Updated : October 30, 2015
Details
FilesGeneric Name:
lumacaftor/ivacaftor
Project Status:
Complete
Therapeutic Area:
Cystic Fibrosis, F508del CFTR mutation
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated.
Call for patient/clinician input open:
Brand Name:
Orkambi
Project Line:
Reimbursement Review
Project Number:
SR0471-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Cystic Fibrosis, F508del CFTR mutation
Recommendation Type:
Do not reimburse
Final Recommendation:
Files
Last Updated : October 30, 2015